Benzinga
Benzinga
Benzinga
venerdì, settembre 25

Prime Medicine Inc

PRMENASDAQ
Trade with Public
Trade with Public
$3.07
-0.06-1.92%
In chiusura: Sep 23, 5:00 PM EST
$3.37
0.247.67%
Pre-mercato: 4:15 AM EST
PRO
Perché si muove?:Prime Medicine shares are trading higher after the company announced the FD...
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Prime Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prime Medicine (PRME).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy
9Buy
2Hold
Consensus RatingOutperform# Analysts13Avg. Consensus PT$10Upside to Avg. PT+206.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026Chardan CapitalKeay NakaeMaintainedBuy$7
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Benzinga Newsdesk

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.
Avi Kapoor

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved